MedPath

Evaluation of Magnesium effects on brain tumor surgery

Early Phase 1
Conditions
neoplasm of brain.
Malignant neoplasm of brain (unspecified)
Registration Number
IRCT201204159475N1
Lead Sponsor
Vise-Challenger of research of Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

eligible patients for brain tumor craniotomy

exclusion criteria of the study:
- creatinine greater than 1.5 mg / dl
- Renal failure and nephrotic syndrome
- Heart rate below 60 beats per minute
- Severe metabolic disorders
- Coagulation disorders (coagulopathy)
- Myasthenia Gravis
- Previous use of magnesium
- Diabetes Mellitus
- Age over 60 or under 18
- GCS score less than 6
- Major cardiopulmonary disease

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
CRP. Timepoint: before intervention, before surgery, after surgery. Method of measurement: ELISA kit.;S100b protein. Timepoint: before intervention, before surgery, after surgery. Method of measurement: ELISA kit.
Secondary Outcome Measures
NameTimeMethod
eurological adverse reactions. Timepoint: After surgery up to 6 month. Method of measurement: Clinical evaluation by neurosurgeon or neurologist.;Pain and bleeding during and after surgery. Timepoint: During and after surgery. Method of measurement: Clinical evaluation by anesthesiologist.
© Copyright 2025. All Rights Reserved by MedPath